The 2008 WHO classification scheme of hematolymphoid neoplasms recognizes a category of myeloid and lymphoid neoplasms (MLNs) with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1.1 The postulated cell of origin for PDGFRA or FGFR1-rearranged diseases is a pluripotent progenitor capable of giving rise to myeloid neoplasms (myeloproliferative neoplasms and acute leukemias) and to lymphoblastic leukemia/lymphoma. Historically, PDGFRB translocations have not been associated with malignancies of the lymphoid lineage. Myeloid neoplasms with abnormalities of PDGFRB have been described to have hematologic features of chronic myelomonocytic leukemia (CMML), sometimes with eosinophilia, or as various other myeloproliferative and/or myelodysplastic neoplasms.2 In recognition of this distinction, the classification scheme designates specific categories of “MLNs” with PDGFRA and FGFR1 rearrangement, but omits the word “lymphoid” from the PDGFRB-associated entity.1 To call attention to the rare occurrence of lymphoid and mixed MLNs with abnormalities of PDGFRB, we present the clinical and pathological details of 2 cases.
References
- WHO classification of tumours of haematopoietic and lymphoid tissues. 2008. Google Scholar
- Holroyd A, Cross NC, Macdonald DH. The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation. Leuk Res. 2011; 35(10):1279-85. PubMedhttps://doi.org/10.1016/j.leukres.2011.05.037Google Scholar
- Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 2001; 98(8):2518-25. PubMedhttps://doi.org/10.1182/blood.V98.8.2518Google Scholar
- Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002; 100(3):1088-91. PubMedhttps://doi.org/10.1182/blood-2002-01-0165Google Scholar
- Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer. 2012; 51(1):54-65. PubMedhttps://doi.org/10.1002/gcc.20930Google Scholar
- Arefi M, Garcia JL, Penarrubia MJ, Queizan JA, Hermosin L, Lopez-Corral L. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Eur J Haematol. 2012; 89(1):37-41. PubMedhttps://doi.org/10.1111/j.1600-0609.2012.01799.xGoogle Scholar
- Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994; 77(2):307-16. PubMedhttps://doi.org/10.1016/0092-8674(94)90322-0Google Scholar
- Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 2003; 36(1):49-59. PubMedhttps://doi.org/10.5483/BMBRep.2003.36.1.049Google Scholar
- Farooqi AA, Waseem S, Riaz AM, Dilawar BA, Mukhtar S, Minhaj S. PDGF: The nuts and bolts of signalling toolbox. Tumour Biol. 2011; 32(6):1057-70. PubMedhttps://doi.org/10.1007/s13277-011-0212-3Google Scholar
- Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 1999; 93(5):1707-14. PubMedGoogle Scholar
- Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22(2):153-66. PubMedhttps://doi.org/10.1016/j.ccr.2012.06.005Google Scholar
- Weston BW, Hayden MA, Roberts KG, Bowyer S, Hsu J, Fedoriw G. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-6. PubMedhttps://doi.org/10.1200/JCO.2012.47.6770Google Scholar
- Chang H, Chuang WY, Sun CF, Barnard MR. Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes. Diagn Pathol. 2012; 7:19. PubMedhttps://doi.org/10.1186/1746-1596-7-19Google Scholar
- Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013; 27(11):2254-6. PubMedhttps://doi.org/10.1038/leu.2013.129Google Scholar